TrialThe Lancet. Infectious diseases2026

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.

John Z Metcalfe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.